E. Ohman J or Asset Management AB Grows Stake in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

E. Ohman J or Asset Management AB raised its stake in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 10.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 257,751 shares of the company’s stock after acquiring an additional 25,000 shares during the period. E. Ohman J or Asset Management AB owned approximately 0.10% of Maravai LifeSciences worth $1,405,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the stock. JPMorgan Chase & Co. grew its stake in shares of Maravai LifeSciences by 1,172.4% in the third quarter. JPMorgan Chase & Co. now owns 4,050,245 shares of the company’s stock worth $33,658,000 after acquiring an additional 3,731,924 shares during the last quarter. Jennison Associates LLC boosted its position in shares of Maravai LifeSciences by 0.3% during the fourth quarter. Jennison Associates LLC now owns 2,990,414 shares of the company’s stock valued at $16,298,000 after buying an additional 9,769 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Maravai LifeSciences by 6.3% during the third quarter. Geode Capital Management LLC now owns 2,752,077 shares of the company’s stock valued at $22,874,000 after buying an additional 162,601 shares during the last quarter. Point72 DIFC Ltd purchased a new stake in shares of Maravai LifeSciences during the third quarter valued at $22,108,000. Finally, Systematic Financial Management LP boosted its position in shares of Maravai LifeSciences by 14.7% during the third quarter. Systematic Financial Management LP now owns 1,612,161 shares of the company’s stock valued at $13,397,000 after buying an additional 206,499 shares during the last quarter. 50.25% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on MRVI shares. Royal Bank of Canada dropped their price objective on Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th. The Goldman Sachs Group cut Maravai LifeSciences from a “neutral” rating to a “sell” rating and dropped their price objective for the company from $7.00 to $4.25 in a research report on Thursday, December 5th. Wolfe Research initiated coverage on Maravai LifeSciences in a report on Thursday, November 14th. They issued a “peer perform” rating on the stock. William Blair reissued a “market perform” rating on shares of Maravai LifeSciences in a report on Friday, November 8th. Finally, Guggenheim initiated coverage on Maravai LifeSciences in a report on Thursday, December 19th. They issued a “neutral” rating on the stock. One research analyst has rated the stock with a sell rating, five have given a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, Maravai LifeSciences currently has an average rating of “Hold” and an average target price of $10.28.

Insider Transactions at Maravai LifeSciences

In related news, General Counsel Kurt Oreshack sold 25,000 shares of Maravai LifeSciences stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $5.03, for a total transaction of $125,750.00. Following the sale, the general counsel now owns 167,618 shares of the company’s stock, valued at approximately $843,118.54. This trade represents a 12.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Carl Hull bought 175,000 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were acquired at an average cost of $5.64 per share, for a total transaction of $987,000.00. Following the purchase, the insider now directly owns 175,000 shares in the company, valued at $987,000. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 0.63% of the company’s stock.

Maravai LifeSciences Stock Up 3.6 %

NASDAQ MRVI opened at $4.94 on Thursday. The stock’s 50-day moving average price is $5.38 and its 200-day moving average price is $7.06. The company has a quick ratio of 9.94, a current ratio of 10.74 and a debt-to-equity ratio of 0.89. Maravai LifeSciences Holdings, Inc. has a 52 week low of $4.28 and a 52 week high of $11.56. The company has a market capitalization of $1.25 billion, a P/E ratio of -3.01 and a beta of -0.08.

Maravai LifeSciences (NASDAQ:MRVI) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.09) EPS for the quarter. Maravai LifeSciences had a negative return on equity of 6.61% and a negative net margin of 81.13%. The company had revenue of $65.20 million during the quarter, compared to the consensus estimate of $67.58 million. During the same period last year, the business earned ($0.02) EPS. On average, equities research analysts predict that Maravai LifeSciences Holdings, Inc. will post -0.24 earnings per share for the current year.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.